Department of Vascular and Endovascular Surgery, Paracelsus Medical University, Nürnberg, Germany.
Department of Vascular and Endovascular Surgery, Paracelsus Medical University, Nürnberg, Germany.
Eur J Vasc Endovasc Surg. 2015 May;49(5):524-31. doi: 10.1016/j.ejvs.2014.11.018. Epub 2015 Jan 17.
To present a 10 year experience with endovascular thoracoabdominal aortic aneurysm (TAAA) repair using fenestrated and branched stent grafts.
Consecutive patients with TAAA treated with fenestrated and branched stent grafts within the period January 2004-December 2013. Data were collected prospectively.
166 patients (125 male, 41 female, mean age 68.8 ± 7.6 years) were treated. The mean TAAA diameter was 71 ± 9.3 mm. Types of TAAA were: type I, n = 12 (7.2%), type II, n = 50 (30.1%), type III, n = 53 (31.9%), type IV, n = 41 (24.8%), and type V, n = 10 (6%). Fifteen (9%) patients had an acute TAAA (11 contained rupture, 4 symptomatic). One hundred and eight (65%) patients were refused for open surgery earlier. Seventy eight (47%) patients had previously undergone one or more open/endovascular aortic procedures. Technical success was 95% (157/166). Thirty day operative mortality was 7.8% (13/166), with an in hospital mortality of 9% (15/166). Peri-operative spinal cord ischemia (SCI) was observed in 15 patients (9%), including permanent paraplegia in two (1.2%). Mean follow up was 29.2 ± 21 months. During follow up 40 patients died, two of them probably from aneurysm related cause. Re-intervention, mostly by endovascular means, was needed in 40 (24%) patients. Estimated survival at 1, 2, and 5 years was 83% ± 3%, 78% ± 3.5%, and 66.6% ± 6.1%, respectively. Estimated target vessel stent patency at 1, 2, and 5 years was 98% ± 0.6%, 97% ± 0.8%, and 94.2% ± 1.5%, respectively. Estimated freedom from re-intervention at 1 and 3 years was 88.3% ± 2.7%, and 78.4% ± 4.5%, respectively.
Endovascular repair of TAAA with fenestrated and branched stent grafts in high volume centers appears safe and effective in the mid-term in a high risk patient cohort. A considerable reintervention rate should be acknowledged, however.
介绍使用开窗和分支支架移植物进行血管内胸腹主动脉瘤(TAAA)修复的 10 年经验。
连续纳入 2004 年 1 月至 2013 年 12 月期间采用开窗和分支支架移植物治疗的 TAAA 患者。数据前瞻性收集。
166 例患者(125 例男性,41 例女性,平均年龄 68.8±7.6 岁)接受了治疗。TAAA 平均直径为 71±9.3mm。TAAA 类型为:I 型,n=12(7.2%);II 型,n=50(30.1%);III 型,n=53(31.9%);IV 型,n=41(24.8%);V 型,n=10(6%)。15 例(9%)患者为急性 TAAA(11 例包含破裂,4 例为症状性)。108 例(65%)患者先前因开腹手术而被拒绝。78 例(47%)患者之前已进行过一次或多次开放/血管内主动脉手术。技术成功率为 95%(157/166)。30 天手术死亡率为 7.8%(13/166),院内死亡率为 9%(15/166)。15 例(9%)患者发生围手术期脊髓缺血(SCI),其中 2 例(1.2%)为永久性截瘫。平均随访 29.2±21 个月。随访期间,40 例患者死亡,其中 2 例可能死于动脉瘤相关原因。40 例(24%)患者需要再次介入治疗,主要通过血管内途径。1、2 和 5 年估计生存率分别为 83%±3%、78%±3.5%和 66.6%±6.1%。1、2 和 5 年估计靶血管支架通畅率分别为 98%±0.6%、97%±0.8%和 94.2%±1.5%。1 年和 3 年估计免于再次干预的比例分别为 88.3%±2.7%和 78.4%±4.5%。
在高风险患者队列中,在高容量中心进行 TAAA 的血管内修复,在中期看来是安全有效的。然而,应承认较高的再干预率。